| Nov 7 |
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
|
| Nov 5 |
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
|
| Oct 31 |
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
|
| Oct 25 |
Molecular Partners prices $20M offering
|
| Oct 25 |
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
|
| Oct 23 |
Molecular Partners Expands Radio-DARPin Collaboration
|
| Oct 4 |
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
|
| Sep 27 |
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
|
| Aug 26 |
Molecular Partners reports 1H results
|
| Aug 26 |
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
|
